Novel CAR-T approaches for ALL
Rebecca Gardner
CAR-T in adult ALL
Claire Roddie
Allogeneic CAR-T in ALL
Bijal Shah
Remission & Persistence
Shannon Maude
Overview
Saar Gill
CART vs BITE for AML
John DiPersio
NKG2D and anti-CD33 CART
David Sallman
Update CLL CAR-T trial landscape/JCAR
Tanya Siddiqi
The role of CLL tumor cells in resistance to anti-CAR-T cell therapy
Joseph Melenhorst
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David Porter
CD19-CAR-T cells – trial updates
Jeremy Abramson
BCMA CART – ready for standard of care practice?
Nina Shah
CART trials in China: myeloma and CART landscape in China
Jianxiang Wang
BITes vs CARs
Herman Einselle
Beyond BCMA, other novel CART targets and combinations
Eric Smith
Tmod CAR T cells Targeting Loss of Heterozygosity
William Go
Repeat CAR T infusions (ALL, NHL and CLL)
Jordan Gauthier
Novel CAR platforms – allogeneic CART, CAR-NK
Michael Hudecek